Clinical Trial Update: A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN) [Phase 2]

View source ↗

Summary

Phase 2 study comparing two doses of AGTC-501 in male participants with X-linked retinitis pigmentosa caused by RPGR mutations; enrollment is ongoing by invitat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Retinitis Pigmentosa

Drugs mentioned

• AGTC-501

Snippet

Sponsor: Beacon Therapeutics | Conditions: X-Linked Retinitis Pigmentosa | Phase 2 | Status: ENROLLING_BY_INVITATION